{
    "clinical_study": {
        "@rank": "1662", 
        "arm_group": [
            {
                "arm_group_label": "Chemotherapy-Naive Patients", 
                "arm_group_type": "Experimental", 
                "description": "VT-464: given orally twice daily in 28-day cycles"
            }, 
            {
                "arm_group_label": "Previous Chemotherapy Patients", 
                "arm_group_type": "Experimental", 
                "description": "VT-464: given orally twice daily in 28-day cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this clinical study is to determine the safety and efficacy of VT-464, a\n      lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer\n      (CRPC) who have been previously treated with enzalutamide."
        }, 
        "brief_title": "Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2 open-label study of VT-464 in patients with progressive, metastatic\n      castration-resistant prostate cancer (mCRPC) who have been previously treated with\n      enzalutamide. The study consists of two cohorts: patients in Cohort 1 must have never\n      received prior chemotherapy and patients in Cohort 2 must have received at least one (and\n      not more) prior course of chemotherapy for mCRPC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Eligibility Criteria:\n\n          -  Patients must have documented histological or cytological evidence of adenocarcinoma\n             of the prostate.\n\n          -  Must have progressive, metastatic castration-resistant prostate cancer (mCRPC). There\n             must be radiographic evidence of disease after primary treatment with surgery or\n             radiotherapy that has continued to progress radiographically or biochemically (rising\n             PSA levels on successive measurements) despite adequate androgen-deprivation therapy,\n             which is defined as having undergone bilateral surgical castration or continued\n             treatment on GnRH agonists or antagonists.\n\n          -  All patients in this trial must have been treated with enzalutamide.\n\n          -  Patients in Cohort 1 will not be allowed to have received prior chemotherapy;\n             patients in Cohort 2 must have received one (and not more) prior course of\n             chemotherapy for mCRPC.\n\n          -  Progression must be evidenced and documented by any of the following parameters:\n\n               -  PSA progression defined by a minimum of two rising PSA levels with an interval\n                  of \u2265 1 week between each determination\n\n               -  Appearance of one or more new lesions on bone scan\n\n               -  Progressive measurable disease by RECIST 1.1"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT02117531", 
            "nct_id": "NCT02130700", 
            "org_study_id": "VMT-VT-464-CL-002"
        }, 
        "intervention": {
            "arm_group_label": [
                "Chemotherapy-Naive Patients", 
                "Previous Chemotherapy Patients"
            ], 
            "description": "Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose", 
            "intervention_name": "VT-464: given orally twice daily in 28-day cycles", 
            "intervention_type": "Drug", 
            "other_name": "VT-464"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "mCRPC", 
            "metastatic", 
            "castration-resistant prostate cancer"
        ], 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "contact": {
                "email": "gchun@mail.nih.gov", 
                "last_name": "Guinevere Chun, RN", 
                "phone": "301-443-4147"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institutes of Health, National Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Ravi Madan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated With Enzalutamide", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the PSA response as defined by a \u2265 50% decrease in serum PSA per the Prostate Cancer Clinical Trials Working Group 2 criteria after each cycle and after 12 weeks of dosing with VT-464 compared to PSA level at baseline in patients who have been previously treated with enzalutamide.", 
                "measure": "The change in PSA from baseline using waterfall plots in response to 12-weeks of treatment with VT-464", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Kaplan-Meier curves of progression-free survival (PFS) will be constructed in each cohort and the median PFS will be determined and informally compared to any available results.", 
                "measure": "Progression-free survival using Kaplan-Meier curves", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02130700"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Survival: will be analyzed similarly to PFS, with a separate Kaplan-Meier curve for each arm. A patient for whom there is no death event will be censored; the censored date will be the date of last contact.", 
                "measure": "Overall survival using Kaplan-Meier curves", 
                "safety_issue": "No", 
                "time_frame": "32 months"
            }, 
            {
                "description": "The safety of VT-464 will be evaluated by laboratory evaluation, electrocardiogram, the report of adverse events and concomitant medications at each 28-day cycle of treatment and 4-5 weeks after therapy has been discontinued.", 
                "measure": "The safety and tolerability of VT-464 by evaluating adverse events, vital signs, physical examination findings, concomitant medications and laboratory tests.", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }, 
            {
                "description": "Maximum PSA response will be descriptive in nature and presented for each cohort as a percent of patients and as a waterfall plot.", 
                "measure": "Maximum PSA response compared to baseline", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }
        ], 
        "source": "Viamet Pharmaceuticals, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Viamet Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}